Literature DB >> 15060148

pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development.

Natalie H Stickle1, Jacky Chung, Jeffery M Klco, Richard P Hill, William G Kaelin, Michael Ohh.   

Abstract

Functional inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene is the cause of the familial VHL disease and most sporadic renal clear-cell carcinomas (RCC). pVHL has been shown to play a role in the destruction of hypoxia-inducible factor alpha (HIF-alpha) subunits via ubiquitin-mediated proteolysis and in the regulation of fibronectin matrix assembly. Although most disease-causing pVHL mutations hinder the regulation of the HIF pathway, every disease-causing pVHL mutant tested to date has failed to promote the assembly of the fibronectin matrix, underscoring its potential importance in VHL disease. Here, we report that a ubiquitin-like molecule called NEDD8 covalently modifies pVHL. A nonneddylateable pVHL mutant, while retaining its ability to ubiquitylate HIF, failed to bind to and promote the assembly of the fibronectin matrix. Expression of the neddylation-defective pVHL in RCC cells, while restoring the regulation of HIF, failed to promote the differentiated morphology in a three-dimensional growth assay and was insufficient to suppress the formation of tumors in SCID mice. These results suggest that NEDD8 modification of pVHL plays an important role in fibronectin matrix assembly and that in the absence of such regulation, an intact HIF pathway is insufficient to prevent VHL-associated tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15060148      PMCID: PMC381603          DOI: 10.1128/MCB.24.8.3251-3261.2004

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  32 in total

1.  Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.

Authors:  M E Cockman; N Masson; D R Mole; P Jaakkola; G W Chang; S C Clifford; E R Maher; C W Pugh; P J Ratcliffe; P H Maxwell
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

2.  VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling.

Authors:  E J Davidowitz; A R Schoenfeld; R D Burk
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

3.  Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.

Authors:  M Ohh; C W Park; M Ivan; M A Hoffman; T Y Kim; L E Huang; N Pavletich; V Chau; W G Kaelin
Journal:  Nat Cell Biol       Date:  2000-07       Impact factor: 28.824

Review 4.  Fibronectin fibrillogenesis: a paradigm for extracellular matrix assembly.

Authors:  J E Schwarzbauer; J L Sechler
Journal:  Curr Opin Cell Biol       Date:  1999-10       Impact factor: 8.382

5.  Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein.

Authors:  M Ohh; Y Takagi; T Aso; C E Stebbins; N P Pavletich; B Zbar; R C Conaway; J W Conaway; W G Kaelin
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

6.  An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association.

Authors:  H T Cohen; M Zhou; A M Welsh; S Zarghamee; H Scholz; D Mukhopadhyay; T Kishida; B Zbar; B Knebelmann; V P Sukhatme
Journal:  Biochem Biophys Res Commun       Date:  1999-12-09       Impact factor: 3.575

7.  Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes.

Authors:  H Okuda; S Hirai; Y Takaki; M Kamada; M Baba; N Sakai; T Kishida; S Kaneko; M Yao; S Ohno; T Shuin
Journal:  Biochem Biophys Res Commun       Date:  1999-09-24       Impact factor: 3.575

8.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

9.  HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.

Authors:  M Ivan; K Kondo; H Yang; W Kim; J Valiando; M Ohh; A Salic; J M Asara; W S Lane; W G Kaelin
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

10.  Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function.

Authors:  C E Stebbins; W G Kaelin; N P Pavletich
Journal:  Science       Date:  1999-04-16       Impact factor: 47.728

View more
  63 in total

1.  First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.

Authors:  Anna Roma; Marco Maruzzo; Umberto Basso; Antonella Brunello; Rita Zamarchi; Elisabetta Bezzon; Fabio Pomerri; Stefania Zovato; Giuseppe Opocher; Vittorina Zagonel
Journal:  Fam Cancer       Date:  2015-06       Impact factor: 2.375

2.  NUB1 suppresses the formation of Lewy body-like inclusions by proteasomal degradation of synphilin-1.

Authors:  Kunikazu Tanji; Tomoaki Tanaka; Fumiaki Mori; Katsumi Kito; Hitoshi Takahashi; Koichi Wakabayashi; Tetsu Kamitani
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 3.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

4.  Insights into Cullin-RING E3 ubiquitin ligase recruitment: structure of the VHL-EloBC-Cul2 complex.

Authors:  Henry C Nguyen; Haitao Yang; Jennifer L Fribourgh; Leslie S Wolfe; Yong Xiong
Journal:  Structure       Date:  2015-02-05       Impact factor: 5.006

5.  Ribosomal proteins are targets for the NEDD8 pathway.

Authors:  Dimitris P Xirodimas; Anders Sundqvist; Akihiro Nakamura; Linnan Shen; Catherine Botting; Ronald T Hay
Journal:  EMBO Rep       Date:  2008-02-15       Impact factor: 8.807

6.  Downregulation of integrins by von Hippel-Lindau (VHL) tumor suppressor protein is independent of VHL-directed hypoxia-inducible factor alpha degradation.

Authors:  Qingzhou Ji; Robert D Burk
Journal:  Biochem Cell Biol       Date:  2008-06       Impact factor: 3.626

Review 7.  Function and regulation of protein neddylation. 'Protein modifications: beyond the usual suspects' review series.

Authors:  Gwénaël Rabut; Matthias Peter
Journal:  EMBO Rep       Date:  2008-09-19       Impact factor: 8.807

8.  pVHL function is essential for endothelial extracellular matrix deposition.

Authors:  Nan Tang; Fiona Mack; Volker H Haase; M Celeste Simon; Randall S Johnson
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

9.  Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification.

Authors:  Qiliang Cai; Suhbash C Verma; Pankaj Kumar; Michelle Ma; Erle S Robertson
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

10.  NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation.

Authors:  T Hosono; T Tanaka; K Tanji; T Nakatani; T Kamitani
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.